TargetBeta
MUC1
mucin 1, cell surface associated · also CD227, PEM, ADMCKD, ADMCKD1 · CD molecules
3 programs in company-led studies act on MUC1, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rule | Xadcera Biopharmaceutical (Suzhou) | phase 2 | 11 running | ERBB3 | NCIt |
| Anti-EGFR/Anti-MUC1 Bispecific Antibody-drug Conjugate NEOK002rule | NEOK Bio | phase 1 | 11 running | EGFR | NCIt |
| Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324rule | Merck KGaA, Darmstadt, Germany | phase 1 | 11 running | CD40 | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Ovarian Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Oct 8, 2027Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002 · Xadcera Biopharmaceutical (Suzhou) · phase 2 · NCT06751329
- Feb 2029Anti-EGFR/Anti-MUC1 Bispecific Antibody-drug Conjugate NEOK002 · NEOK Bio · phase 1 · NCT07612189
- Feb 23, 2029Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324 · Merck KGaA, Darmstadt, Germany · phase 1 · NCT07166601
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.